Trial reportCancer research communications2026
A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden.
Trial report in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy (TEMPLE) study was a phase Ib/II trial evaluating the safety, tolerability, and efficacy of atezolizumab combined with thiopurine therapy in patients with metastatic solid tumors, aiming to increase tumor mutational burden (TMB) through single-nucleotide mismatching and neoepitope generation. PATIENTS AND
methodsPhase Ib was an open-label, single-arm dose de-escalation trial conducted to determine the recommended phase II dose (RP2D) of 6-mercaptopurine (6MP) and 6-thioguanine (6TG) combined with atezolizumab in adult patients with metastatic solid tumors harboring intermediate TMB (5-10 mutations per megabase). Phase II used a Simon two-stage design to assess objective response per RECIST v1.1. Secondary endpoints included overall survival and progression-free survival.
resultsIn phase Ib, the initial dose level proved too toxic in this heavily pretreated population. The subsequent dose level (6MP 37.5 mg/m2 every day + 6TG 10 mg/m2 every day + atezolizumab 1,200 mg every 3 weeks) was well tolerated and defined as the RP2D. The most common treatment-related adverse events were anorexia, nausea, and fatigue. In phase II stage 1, 3 of 13 patients achieved stable disease, whereas the remaining 10 patients experienced progressive disease. No objective responses were observed, and the trial was terminated after stage 1. Translational analyses of serial tumor biopsies using whole-genome and RNA sequencing revealed no definitive shifts in TMB or neoepitope generation.
conclusionsA safe and tolerable dose of 6MP and 6TG combined with atezolizumab was identified in patients with metastatic solid tumors. Although clinical benefit was limited, the TEMPLE study informs future investigations in patients with less advanced disease. SIGNIFICANCE: The TEMPLE study investigated a novel translational strategy aimed at increasing tumor immunogenicity through thiopurine-induced single-nucleotide mismatching, thereby enhancing neoepitope generation and potentially sensitizing tumors to PD-L1 blockade. A safe and tolerable combination treatment regimen was established; however, no objective responses were observed in this heavily pretreated and heterogeneous patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.